⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 6, 2025Open Access

Table 4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Christopher H. Lieu Heinz‐Josef Lenz Al B. Benson Xue Meng Uk-Il Kim Song Hyun Kim Kyungjin Kim Moo Je Sung

View Full Paper

Ask AI

Bookmark

Share

Key Points

Patients experienced stable disease while receiving basroparib, indicating possible effectiveness.
The study involves analyzing data from patients with advanced-stage solid tumors treated with basroparib.
This phase I study focuses on dose escalation in assessing safety and initial effectiveness of the tankyrase inhibitor.
The findings highlight the need for further research into basroparib's potential in treating these tumors.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase I study evaluates basroparib for stable disease in advanced-stage solid tumors, suggesting potential efficacy.

Abstract

Summary of stable disease patients data.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lieu et al. (2025) studied this question.

synapsesocial.com/papers/68e62de1a8c0c6d45873feb7 https://doi.org/10.1158/2767-9764.30284989

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
2Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
3Figure 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
4Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
5Data from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025

More related papers

A First-In-Human Dose-Escalation Phase 1 Study of Basroparib (STP1002), a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
TABLE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
TABLE 1 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors2024